focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

4 Apr 2024 13:59

RNS Number : 3751J
Evgen Pharma PLC
04 April 2024
 

4 April 2024

Evgen Pharma plc

 

("Evgen", the "Company" or the "Group")

 

Result of General Meeting

and

Total Voting Rights

 

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces that at the General Meeting held at 10:00 a.m. at the offices of Cavendish, One Bartholomew Close, London, EC1A 7BL on 4 April 2024, the Resolutions proposed were duly passed by way of a show of hands.

 

Details of the proxy voting instructions lodged prior to the General Meeting for each Resolution are shown on the company's website.

 

Total Voting Rights

 

The New Ordinary Shares to be issued pursuant to the Fundraising are expected to be Admitted to trading on 5 April 2024. Following Admission of the New Ordinary Shares, the total number of Ordinary Shares in issue will be 427,346,895, with no shares held in treasury. This is the figure that may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Unless otherwise defined herein, terms used in this announcement have the meaning given to them in the Acquisition, Fundraising and Change of Name announcement dated 19 March 2024. A further announcement shall be made regarding the Company's change of name in due course.

 

Enquiries

Evgen Pharma plcDr Huw Jones, CEO Toni Hänninen, CFO

Dr Helen Kuhlman, CBO

+44 (0)1625 315 090enquiries@evgen.com

Cavendish Capital Markets (NOMAD and Broker) Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)Nigel Birks / Harriet Ward (ECM)

+44 20 7220 0500

Instinctif Partners

Melanie Toyne-Sewell / Jack Kincade

+44 207 457 2020Evgen@Instinctif.com

 

About Evgen Pharma plc

 

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane. 

 

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands.

 

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. Recently, Evgen completed an out-licensing transaction with Stalicla SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of $160.5m and a double-digit royalty on sales.

 

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol EVG. 

 

For further information, please visit: www.evgen.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMUSVURSBUSRAR
Date   Source Headline
7th Dec 201111:51 amRNSForm 8.5 (EPT/RI)
7th Dec 201111:26 amRNSForm 8.5 (EPT/RI)
7th Dec 20119:48 amBUSForm 8.3 - Evolution Group Plc
6th Dec 20115:27 pmRNSHolding(s) in Company
6th Dec 20114:38 pmRNSForm 8.3 - Evolution Group PLC
6th Dec 20113:01 pmBUSForm 8.3 - Evolution Group Plc
6th Dec 20113:00 pmRNSForm 8.3 - EVOLUTION GROUP PLC
6th Dec 20112:51 pmBUSForm 8.3- EVOLUTION GROUP PLC
6th Dec 20112:38 pmRNSForm 8.3 - Evolution Group PLC
6th Dec 201112:49 pmRNSForm 8.3 - Investec Plc
6th Dec 201112:05 pmRNSHolding(s) in Company
6th Dec 201111:10 amRNSForm 8.5 (EPT/RI)
6th Dec 201110:11 amRNSHolding(s) in Company
6th Dec 20119:44 amRNSForm 8.3 - Evolution Group PLC
5th Dec 20113:04 pmPRNForm 8.3 - Evolution Group Plc
5th Dec 20113:02 pmRNSForm 8.3 - EVOLUTION GROUP PLC
5th Dec 20113:01 pmRNSForm 8.3 - Evolution Group PLC
5th Dec 20112:59 pmRNSForm 8.3 - Evolution Group PLC
5th Dec 20112:06 pmBUSForm 8.3 - Evolution Group Plc
5th Dec 20111:38 pmBUSForm 8.3 - EVOLUTION GROUP PLC
5th Dec 201112:25 pmRNSForm 8.3 -Investec Limited
5th Dec 201111:46 amRNSForm 8.5 (EPT/RI) - Evolution Group Plc
5th Dec 201111:40 amRNSForm 8.5 (EPT/RI)
5th Dec 201111:15 amBUSForm 8.3 - Evolution Group Plc
2nd Dec 20112:31 pmRNSForm 8.3 - Evolution Group PLC
2nd Dec 20112:11 pmBUSForm 8.3 - EVOLUTION GROUP PLC
2nd Dec 20111:54 pmBUSForm 8.3 - Evolution Group Plc
2nd Dec 20111:04 pmRNSForm 8.3 -Investec Limited
2nd Dec 201112:53 pmRNSForm 8.3 -Investec Plc
2nd Dec 201112:18 pmRNSForm 8.5 (EPT/RI) - Evolution Group Plc
2nd Dec 201111:52 amRNSForm 8.5 (EPT/RI)
1st Dec 20113:18 pmBUSForm 8.3 - EVOLUTION GROUP PLC
1st Dec 20113:12 pmRNSForm 8.3 - Investec Plc
1st Dec 20113:08 pmRNSMerger Update
1st Dec 20113:00 pmRNSForm 8.3 - EVOLUTION GROUP PLC
1st Dec 20112:41 pmBUSForm 8.3 - Evolution Group Plc
1st Dec 20112:29 pmBUSForm 8.3 - Evolution Group PLC
1st Dec 20112:26 pmRNSForm 8.3 - Evolution Group PLC
1st Dec 20112:25 pmRNSForm 8.3 - Evolution Group PLC
1st Dec 201112:04 pmRNSForm 8.3 -Investec Limited
1st Dec 201112:01 pmRNSForm 8.3 -Investec Plc
1st Dec 201111:58 amRNSForm 8.5 (EPT/RI) - Evolution Group Plc
1st Dec 201111:48 amRNSForm 8.5 (EPT/RI)
1st Dec 201110:50 amBUSForm 8.3 - EVOLUTION GROUP PLC
30th Nov 20113:35 pmPRNForm 8.3 - Evolution Group Plc
30th Nov 20113:27 pmRNSForm 8.3 - Evolution Group PLC
30th Nov 20113:00 pmRNSForm 8.3 - EVOLUTION GROUP PLC
30th Nov 20112:01 pmBUSForm 8.3 - Evolution Group PLC
30th Nov 201112:53 pmRNSForm 8.3 - Investec Plc
30th Nov 201112:47 pmRNSForm 8.3 - Investec Limited

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.